Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras

Crassula Honduras Announces the Launch of Glycedil, Sitagliptin 100mg, in Honduras

Tegucigalpa, Honduras – In a significant expansion of its diabetes care portfolio, Crassula Pharmaceuticals proudly introduces Glycedil, a Sitagliptin 100mg tablet, to the Honduran market. This strategic launch underscores Crassula’s unwavering commitment to innovating in the field of chronic disease management and improving the quality of life for individuals living with Type 2 diabetes.

Sitagliptin, the active ingredient in Glycedil, is a highly effective dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by enhancing the body’s own ability to lower blood sugar levels, especially after meals. The 100mg dosing of Glycedil is designed to optimize blood sugar control while minimizing side effects, offering a new hope for patients seeking a more balanced approach to managing their diabetes.

“Crassula Pharmaceuticals is dedicated to advancing healthcare outcomes with accessible, innovative treatments. The launch of Glycedil is a testament to our commitment to providing effective solutions for the complex challenges faced by patients with Type 2 diabetes,” said Dr. Josué Daniel Suazo, National Sales Manager at Crassula Honduras. “We are excited to offer this new therapeutic option to the people of Honduras, further enhancing our mission to make advanced care available to all.”

Glycedil is now available across Honduras, marking a pivotal step forward in the management of Type 2 diabetes. For more information on Glycedil and other Crassula products, please visit  or contact

About Crassula Honduras

Crassula Honduras is a division of Crassula LLC., a USA based company at the forefront of developing high-quality healthcare products, focusing on innovation, quality, and patient safety to improve health and well-being both in Honduras and internationally. With a diverse product range that addresses a wide spectrum of therapeutic areas, Crassula is committed to meeting the healthcare needs of communities around the globe.

Leave a Reply

Your email address will not be published. Required fields are marked *